Senores Pharmaceuticals Ltd has received marketing authorisations from the Philippine Food and Drug Administration for 10 products across cardiovascular, CNS and pain-management therapies.

The company said the approvals mark a key step in its strategy to deepen its presence in Southeast Asia and broaden access to affordable treatments.

The basket of products approved addresses a combined market size of $23 million in the Philippines, offering Senores a meaningful entry point in one of the region’s high-growth healthcare markets.

“These approvals reaffirm our commitment to delivering high-quality, affordable treatments for patients,” said Managing Director Swapnil Shah. “Philippines is a critical market in our regional expansion strategy, and this achievement strengthens our position as

See Full Page